Canton Strategic(NASDAQ) CNTN

Canton helps financial institutions use blockchain for secure transactions. It also develops medicines for emergency responders and patients with chronic inflammation. Its work aims to make finance safer and healthcare more accessible.

Products and Services

• Digital Asset Treasury: Manages Canton Coin, a digital asset, for institutional blockchain use (0% of revenue).
• Network Validation: Operates as a Super Validator on the Canton Network, supporting blockchain security (0% of revenue).
• Biotech R&D: Develops medicines for opioid exposure and chronic inflammation, targeting military, first responders, and patients (0% of revenue).
• Token Management: Engages in digital asset lending, locking, and derivatives for treasury optimization (0% of revenue).
• Strategic Investments: Invests in blockchain applications and biotech innovations (0% of revenue).

Growth and Expansion

• Shifted focus to digital asset treasury in late 2025 after raising $545 million in a private placement.
• Rebranded from Tharimmune to Canton in February 2026 to reflect new strategy.
• Launched at-the-market equity program in 2025, with up to $64.9 million initially available for future funding; this limit was expanded to $300 million under an amended agreement in March 2026.
• Expanded biotech pipeline through licensing from Intract Pharma Limited in 2025.
• Became approved to operate as a Super Validator on the Canton Network in early 2026, deepening blockchain involvement.

What Makes Canton Stand Out

Canton combines digital asset management with clinical-stage biotech research, a rare dual focus. Its blockchain operations target regulated financial markets, emphasizing privacy and compliance. The company holds patents for drug delivery technologies, supporting long-term innovation.

Five Things You Need to Know

• No revenue was reported for 2023–2025; financial results consist of interest income and changes in digital asset values.
• Net loss was $35.92 million in 2025, up 194% from 2024.
• Raised $545 million in November 2025 and $54.9 million in January 2026.
• Digital assets held were $501.76 million as of December 31, 2025.
• Operating expenses rose to $20.11 million in 2025, up 62% from 2024.

Bottom Line

Canton has evolved from biotech to a dual focus on digital assets and drug development. Its strategy relies on innovation, capital raises, and navigating regulatory challenges.